Humacyte, Inc. (HUMA)
| Market Cap | 274.79M |
| Revenue (ttm) | 818,000 |
| Net Income (ttm) | -58.73M |
| Shares Out | 158.84M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,168,700 |
| Open | 1.600 |
| Previous Close | 1.610 |
| Day's Range | 1.590 - 1.740 |
| 52-Week Range | 1.150 - 6.770 |
| Beta | 1.87 |
| Analysts | Strong Buy |
| Price Target | 10.88 (+528.9%) |
| Earnings Date | Nov 7, 2025 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HUMA stock is "Strong Buy." The 12-month stock price target is $10.88, which is an increase of 528.90% from the latest price.
News
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted ...
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surg...
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress
I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles...
Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess...
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commerc...
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities D...
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at comme...
Humacyte: Revenue Ramp From Symvess Incoming
Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M ...
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at comme...
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at comme...
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Fo...
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commerci...
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason -...
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commer...
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
Trestle Bio Announces Research Collaboration with Humacyte
SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing uni...
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
– Patent provides coverage into 2040 for key aspects of the bioreactor manufacturing system – – Symvess, the acellular tissue engineered vessel, is manufactured in this patented system – DURHAM, N.C.,...